Over 52 weeks, the 36 mg dose of Lilly's daily pill lowered HbA1c by 2.1% and weight by 8%, with 14% stopping over side effects, mostly GI.
Recap by typeshit. Full story at Endocrinology Advisor.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
BCG found GLP-1 users plan to spend 11% more on high-protein food, while Reuters found brands inflating protein claims with bigger serving sizes.
The story looks at how longevity and optimization podcasts hype experimental peptides, and where the claims fall short.
Loading…